Pepgra has best of breed practices in neurologic and psychiatric development as well as local and global regulatory insight to successfully meet the unique challenges of neuroscience clinical development. Our doctors are leaders in Phase I-IV neuroscience/central nervous system (CNS) trials around the world across numerous areas of neurology, pain and psychiatry.

CVD trials are massive and multiyear, with unique demands on recruitment and retention; thus programs must be adaptable among sites and countries. We can recommend our native experts for your drug development. CVD trials require a maze of services that determine success. Our solution for this is to leverage a powerful yet operational acumen, well-considered team composition, detailed communication strategies, proven recruitment and retention plans, and adept adjudication—25+ years of collaboration with renowned academic research organizations.

Pharmacotherapy for chronic inflammatory disease (CID) is a crowded field. Yet we have maintained a strong presence since participating in the development of leflunomide and anakinr. Today, biologics are major players. Exciting growth in large-molecule therapies includes first-in-class inhibitors of mPGES-1, Bruton’s tyrosine kinase, and Nod inflammasomes. Blockers of IL-17 and cell adhesion molecule (CAM) inhibitors are hot areas. The debut of biosimilars has raised the stakes. Our doctors are experienced explorers in this universe of pathogens and agents. We provide tailored strategies supported by close relationships with key opinion leaders, seasoned practitioners, and extensive investigator networks in optimal countries.

Serious and devastating—are the words to describe orphan and rare diseases. However, preliminary knowledge underlying mechanisms is not available. Many of them are so rare that the probability of finding physicians, even specialists, who have encountered the condition is negligible. These encumbrances extend to site finding, medical management, administration of specific tests and procedures, and logistical control. Our answer: Pepgra CROs will be your aid when it comes to deploying specialists on the field and leveraging resources.

In addition to our core therapeutic areas in clinical research – Neuroscience/Central Nervous System, Cardiovascular, Immune-Mediated Inflammatory Disorders and Rare Disease – our clinicians, scientists and medical experts at Pepgra Healthcare have successfully completed studies in a wide range of therapeutic areas, including Oncology and Respiratory Disorders. This diverse therapeutic footprint is a reflection of our legacy at Pepgra Healthcare, which has emphasized methodological rigor and problem-solving capabilities as a core differentiator that applies across therapeutic areas. Our endeavor to closely working with our sponsors to meet their unique scientific, medical and commercial needs – combined with our world reach and deep scientific and medical expertise – enable us to successfully execute complex clinical development trials.